News

Number of news items returned: 101 to 120 records of 407

Happy new year of the Rooster - Funding Strategies Connect January 2017

20 January 2017

(13011 views)

 Happy new year of the Rooster - Funding Strategies Connect January 2017 Dear Readers, I would like to wish you a healthy, ...

Nelson Resources Lodges Replacement Prospectus

18 January 2017

(13529 views)

  "The Nelson Resources Limited Board is pleased to advise that Nelson Resources Limited has lodged its Replacement Prospectus to raise ...

Director Briefing with Douglas Bucknell from Tailored Superannuation Solutions

17 January 2017

(12642 views)

  Please read the full briefing via the link below. For more information about Tailored Superannuation Solutions Ltd, please click here.  

"Australian Army Selects Ocular Robotics’ Immersive Telepresence System to be Trialed in Army Units in 2017"

17 January 2017

(12623 views)

  "Following from Ocular Robotics initial selection to demonstrate an Immersive Telepresence System at Army Innovation Day (AID16) in October 2016, ...

Opmantek reports bumper half year result

17 January 2017

(12490 views)

 OPMANTEK REPORTS BUMPER HALF YEAR RESULT " An increase in SaaS (software as a service) subscription contracts has seen Opmantek achieve their ...

Director Briefing with Laurence Baum from BioCube

19 December 2016

(13732 views)

  Please read the full briefing via the link below. For more information about The BioCube Corporation Ltd, please click here.  

"End of year super reforms surge in preparation for 2017"

15 December 2016

(13779 views)

  "End of year super reforms surge in preparation for 2017" "In the last month, the first public skirmishes of a reform ...

"The rebirth of crowd funding in Australia!"

15 December 2016

(13723 views)

" The rebirth of crowd funding in Australia!" " Introduction In December 2015, the Corporations Amendment (Crowd-sourced Funding) Bill 2015 (2015 Bill) was ...

"Turnbull government’s crowdfunding bill ‘flawed’ "

12 December 2016

(13557 views)

"Turnbull government’s crowdfunding bill ‘flawed’"    "The federal government’s proposed framework for equity crowdfunding is counter-productive to the aims of internet-enabled finance, ...

Director Briefing with Adam Schofield from Nelson Resources Limited

09 December 2016

(14158 views)

Please read the full briefing via the link below.  For more information about Nelson Resources Limited, please click here. 

With best wishes for the festive season - Funding Strategies Connect Dec 2016

07 December 2016

(11801 views)

With best wishes for the festive season - Funding Strategies Connect Dec 2016      Dear Readers,   In this, our final newsletter for 2016, ...

Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles

28 November 2016

(14435 views)

 Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles   "Isn’t it time the superannuation industry got real, started concentrating on ...

Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events

25 November 2016

(14461 views)

   Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events    Douglas Bucknell, Managing Director of Tailored Superannuation Solutions Ltd, has announced that ...

Nelson Resources Announce Additional Road Show Dates

25 November 2016

(14077 views)

  Nelson Resources Announce Additional Road Show Dates   The Nelson Resources team are in Sydney on Wednesday, 30th November and Thursday, 1st ...

The superannuation industry is ripe for change and disruption is here

24 November 2016

(13915 views)

" The superannuation industry is ripe for change and disruption is here" " The industry association ASFA, CEO Martin Fahy certainly thinks so ...

ASX Rule Changes - A Summary

11 November 2016

(14635 views)

  "The Australian Securities Exchange (ASX) has just released their revised rule changes that will take effect from 19 December 2016. We ...

BlueMount Capital Chinese Presentation Nov16

09 November 2016

(10323 views)

 The 'China Angle' BlueMount Capital offers a number of Chinese capabilities as shown in the slide below:     Please view the full presentation ...

Trac Group welcomes Elon Musk to roof party

08 November 2016

(9443 views)

  Trac Group welcomes Elon Musk to roof party   "Building products company Trac Group Holdings has welcomed billionaire Elon Musk’s planned expansion into ...

ASX Listing, Company Updates and Introductions - Funding Strategies Connect Nov 2016

04 November 2016

(14047 views)

ASX Listing, Company Updates and Introductions - Funding Strategies Connect Nov 2016 Dear Readers, I hope you enjoyed the Melbourne Cup festivities ...

"Get up to 50% of your export marketing costs back with Nifty Forms"

02 November 2016

(14397 views)

    "Get up to 50% of your export marketing costs back with Nifty Forms Nifty Forms is an online platform enabling startups ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625